Anthony J. Bilotta

TL;DR: It is shown that microbiota-derived short-chain fatty acids (SCFAs) promote IL-22 production by CD4+ T cells and ILCs through G-protein receptor 41 (GPR41) and inhibiting histone deacetylase (HDAC) and that SCFA supplementation enhances IL- 22 production, which protects intestines from inflammation.

TL;DR: The studies demonstrated that microbiota metabolites SCFA promoted IEC RegIIIγ and β-defensins in a GPR43-dependent manner, providing a novel pathway by which microbiota regulates IEC expression of AMP and intestinal homeostasis.

TL;DR: This review highlights the functions of SCFAs and their roles in the pathogenesis of IBD to provide insights into their potential therapeutic application for the treatment of I BD for the purposes of precision medicine.

TL;DR: It is reported that depletion of gut bacteria significantly decreased mucosal and systemic Ab responses in mice orally immunized with OVA and CT and feeding mice short-chain fatty acids promoted Ab responses elicited by CT, and, more importantly, rescuedAb responses in antibiotic-treated mice.

TL;DR: It is demonstrated that neutrophils enhanced production of amphiregulin (AREG), a member of the EGFR ligand family, by IECs, which promoted IEC barrier function and tissue repair, and neutrophil-derived TGF-β promoted AREG production by I ECs.